1. Strathclyde’s natural products and assay facilities SIDR

2. Finding the hits you need for successful drug discovery and consumer health projects Strathclyde’s natural products and assay facilities SIDR

3. What you get powerful chemical library flexible facilities experienced and friendly team

4. Success in drug discovery is not dependent on –size of the screening collection –ultra-high throughput assays

5. Success in drug discovery does need –assay that is relevant to the end purpose –highly diverse chemistry set

6. Highly diverse chemistry set a)combichem b) natural products c) drugs

7. Origin of drugs 1981-2006: 1184 FDA-approved NCEs % total

8. Strathclyde’s resource

9. A drug discovery resource that is better than the competition’s

10. more biodiversity = more chemical diversity

11. A drug discovery resource that is better than the competition’s more biodiversity = more chemical diversity Scotland is not one of the world’s biodiversity hotspots

12. A drug discovery resource that is better than the competition’s more biodiversity = more chemical diversity –worldwide network –genetic diversity

13. SIDR’s Natural Product Network Uzbekistan Nigeria Argentina Chile Sudan Kenya Sri Lanka Malaysia Uruguay Cameroon UK Costa Rica PNG Fiji USA Peru South Africa Australia Korea

14. Genetic diversity

15. SIDR’s screening resources ~90% of plant families ~7,000 species of plants

16. What more do you get?

17. Flexible access chemistrybiology

18. Flexible access chemistry –samples for testing –96-well plates –isolation and structural elucidation –links with Drug Discovery Portal and med-chem biology

19. Flexible access chemistrybiology –molecular and cell- based assays –versatile detection  radioactivity  visible and uv light  chemiluminescence  fluorescence –96-well or 384-well formats

20. Work with an experienced and friendly team

21. Current assays cancer –anti-proliferative/ cytotoxicity assays on 20 human cancer cell lines –kinase inhibitors –cell adhesion blockers

22. Current assays cancer –anti-proliferative/ cytotoxicity assays on 20 human cancer cell lines –kinase inhibitors –cell adhesion blockers infection –S. aureus –E. coli –TB (M. marinum, N. farcinica) –parasitic diseases –cell growth and biofilm disruption

23. Current assays inflammation –anti-oxidant –cell proliferation –cell adhesion –TNF  signalling –NF  B pathway –kinases

24. Current assays inflammation –anti-oxidant –cell proliferation –cell adhesion –TNF  signalling –NF  B pathway neuro/metabolic –Alzheimer’s –analgesia –migraine –stroke –obesity –diabetes

25. Current “hit-to-lead” assays ADME-tox –hERG – cardiac toxicity –CACO2 – cellular absorption –micronucleus formation – genotoxicity –P450s – metabolic stability/drug interactions

26. Open for business contact: a.l.harvey@strath.ac.uk 0141 553 4155a.l.harvey@strath.ac.uk more details: www.sidr.org